Total Valuation
Lexaria Bioscience has a market cap or net worth of $13.88M. The enterprise value is $7.45M.
Market Cap$13.88M
Enterprise Value$7.45M
Share Statistics
Lexaria Bioscience has 24,787,445 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding24,787,445
Owned by Insiders4.58%
Owned by Institutions1.91%
Financial Efficiency
Lexaria Bioscience’s return on equity (ROE) is -3.98 and return on invested capital (ROIC) is -438.07%.
Return on Equity (ROE)-3.98
Return on Assets (ROA)-2.85
Return on Invested Capital (ROIC)-438.07%
Return on Capital Employed (ROCE)-4.43
Revenue Per Employee100.85K
Profits Per Employee-1.70M
Employee Count7
Asset Turnover0.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lexaria Bioscience is ―. Lexaria Bioscience’s PEG ratio is -0.03.
PE Ratio―
PS Ratio22.44
PB Ratio5.30
Price to Fair Value5.30
Price to FCF-1.51
Price to Operating Cash Flow-1.46
PEG Ratio-0.03
Income Statement
In the last 12 months, Lexaria Bioscience had revenue of 705.92K and earned -11.90M in profits. Earnings per share was -0.66.
Revenue705.92K
Gross Profit703.20K
Operating Income-11.88M
Pretax Income-11.91M
Net Income-11.90M
EBITDA-11.82M
Earnings Per Share (EPS)-0.66
Cash Flow
In the last 12 months, operating cash flow was -9.37M and capital expenditures -95.06K, giving a free cash flow of -9.47M billion.
Operating Cash Flow-9.37M
Free Cash Flow-9.47M
Free Cash Flow per Share-0.38
Dividends & Yields
Lexaria Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change-35.93%
50-Day Moving Average0.64
200-Day Moving Average0.82
Relative Strength Index (RSI)42.71
Average Volume (3m)986.05K
Important Dates
Lexaria Bioscience upcoming earnings date is Apr 14, 2023, After Close (Confirmed).
Last Earnings DateJan 18, 2023
Next Earnings DateApr 14, 2023
Ex-Dividend Date―
Financial Position
Lexaria Bioscience as a current ratio of 2.32, with Debt / Equity ratio of 1.43%
Current Ratio2.32
Quick Ratio2.32
Debt to Market Cap0.00
Net Debt to EBITDA0.14
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lexaria Bioscience has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lexaria Bioscience EV to EBITDA ratio is -1.20, with an EV/FCF ratio of -1.35.
EV to Sales20.05
EV to EBITDA-1.20
EV to Free Cash Flow-1.35
EV to Operating Cash Flow-1.35
Balance Sheet
Lexaria Bioscience has $5.27M in cash and marketable securities with $94.39K in debt, giving a net cash position of $5.18M billion.
Cash & Marketable Securities$5.27M
Total Debt$94.39K
Net Cash$5.18M
Net Cash Per Share$0.21
Tangible Book Value Per Share$0.13
Margins
Gross margin is 100.00%, with operating margin of -1683.01%, and net profit margin of -1686.00%.
Gross Margin100.00%
Operating Margin-1683.01%
Pretax Margin-1687.36%
Net Profit Margin-1686.00%
EBITDA Margin-1674.91%
EBIT Margin-1687.36%
Analyst Forecast
The average price target for Lexaria Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-30.03%
EPS Growth Forecast18.00%